Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow IKT
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
0.02 | 0.38 | 0.02 | 13.95 | 40.75 | 23.05 | 13.25 | 97.54 | 178.76 |
Receivables |
0.18 | 0.47 | — | 0.77 | 0.11 | 0.04 | — | — | — |
Other current assets |
0.00 | 0.40 | 0.02 | 0.77 | 0.11 | 1.12 | 0.22 | 0.08 | 1.00 |
Total current assets |
0.20 | 1.25 | 0.04 | 14.78 | 42.47 | 24.37 | 14.21 | 98.45 | 180.11 |
Property, Plant, Equpment (Net) |
— | — | — | — | — | 0.24 | 0.07 | 0.05 | — |
Long-term assets (Other) |
— | 1.59 | 0.00 | — | — | — | — | — | 1.10 |
Total non-current assets |
— | 1.59 | 0.00 | — | — | 0.57 | 0.30 | 0.15 | 1.10 |
Total Assets |
— | 2.85 | 0.04 | 14.78 | 42.47 | 24.94 | 14.51 | 98.60 | 181.20 |
Notes Payable |
— | 0.23 | 0.10 | 0.04 | 0.25 | — | — | — | — |
Accounts Payable |
0.35 | 0.95 | 1.00 | 1.72 | 1.09 | 1.15 | 0.65 | 0.94 | 1.16 |
Accrued Expenses |
— | 2.17 | 1.72 | 0.63 | 2.72 | 2.40 | 2.26 | 2.68 | 4.08 |
Current Part of Debt |
0.46 | — | — | — | — | — | — | — | — |
Current Revenue (Deferred) |
— | 0.26 | 1.43 | 2.33 | — | — | — | — | — |
Other current liabilities |
0.91 | 2.44 | 3.15 | 2.96 | 2.72 | 2.40 | — | — | 3.06 |
Total current liabilities |
1.73 | 3.62 | 4.25 | 4.72 | 4.05 | 3.70 | 3.44 | 3.73 | 8.30 |
Non-current Liabilities (Other) |
— | — | 0.28 | 0.28 | — | — | — | — | — |
Total non-current liabilities |
— | — | 0.28 | 0.28 | — | 0.21 | 0.09 | — | — |
Total liabilities |
1.73 | 3.62 | 4.53 | 5.00 | 4.05 | 3.90 | 3.53 | 3.73 | 8.30 |
Additional Paid In Capital |
— | 5.67 | 7.69 | 24.81 | 68.21 | 68.80 | 77.87 | 189.25 | 315.43 |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.00 | 0.01 | 0.07 | 0.13 |
Retained Earnings |
(4.31) | (6.46) | (12.18) | (15.03) | (29.82) | (47.87) | (66.90) | (94.42) | (142.68) |
Common Equity (Total) |
(1.44) | (0.78) | (4.49) | 9.78 | 38.42 | 21.04 | 10.98 | 94.87 | 172.90 |
Shareholders Equity (Total) |
(1.44) | (0.78) | (4.49) | 9.78 | 38.42 | 21.04 | 10.98 | 94.87 | 172.90 |
Shareholders Equity and Liabilities (Total) |
— | 2.85 | 0.04 | 14.78 | 42.47 | 24.94 | 14.51 | 98.60 | 181.20 |
Shares (Common) |
— | 1.37 | 1.36 | 1.68 | 4.19 | 4.22 | 6.19 | 69.36 | 131.69 |
Shareholders Equity (Tangible) |
— | (0.78) | (4.49) | 9.78 | 38.42 | 21.04 | 10.98 | 94.87 | 172.90 |
Net Debt |
0.44 | (0.38) | (0.02) | (13.95) | (40.75) | (23.05) | (13.25) | (97.54) | (178.76) |
Total Debt |
0.46 | 0.23 | 0.37 | 0.32 | 0.25 | 0.35 | — | — | — |